A multicentre single arm study to evaluate the safety and efficacy of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (TE NDMM) patients refractory to initial bortezomib-based induction therapy (MM17)
收藏DataCite Commons2023-08-31 更新2024-07-13 收录
下载链接：
https://www.allg.org.au/datasets/mm17/
下载链接
链接失效反馈官方服务：
资源简介：
HeSANDA 1.0.0
提供机构：
Australasian Leukaemia and Lymphoma Group (ALLG)
创建时间：
2023-06-07
